Katherine Borden

Dr. Borden’s research program focuses on a particular protein, the eIF4E, and how its dysregulation leads to transformation and leukemia. A better understanding of the function and subsequent biochemical underpinnings of this protein could prove useful in the development of therapies to treat leukemia. One such therapy is ribavirin, which successfully targeted eIF4E in poor prognosis acute myeloid leukemia (AML) leading to remissions in some patients. Ongoing trials are focused on increasing the durability and frequency of remissions by combining ribavirin with other agents.